Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 9, 2011, Pages 1381-1391

  Seidel, Matthias F ^a   Müller, Wolfgang ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antidepressants; differential therapy; fibromyalgia syndrome; pregabalin; serotonin receptor antagonists; subgroups

Indexed keywords

AMITRIPTYLINE; BRADYKININ; CARISOPRODOL; CYCLOBENZAPRINE; DICLOFENAC; DIPYRONE; DULOXETINE; FLUOXETINE; IBUPROFEN; IMIPRAMINE; INTERLEUKIN 1BETA; LEUKOTRIENE; MAPROTILINE; MILNACIPRAN; MORPHINE; PARACETAMOL; PREGABALIN; PROSTAGLANDIN; SEROTONIN 2A AGONIST; SEROTONIN 3 AGONIST; TIZANIDINE; TRAMADOL; TRIMIPRAMINE; TROPISETRON;

ABDOMINAL COMPARTMENT SYNDROME; ANXIETY DISORDER; ARTHRALGIA; CONSTIPATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FIBROMYALGIA; HEADACHE; HUMAN; LOW BACK PAIN; NEUROGENIC INFLAMMATION; NOCICEPTIVE STIMULATION; OPEN STUDY; PARESTHESIA; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT DURATION; VISUAL DISORDER; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; FIBROMYALGIA; HUMANS; PSYCHOTHERAPY; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS;

EID: 79956098262     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.557362     Document Type: Review

References (105)

1. Wolfe F, Smythe HA, Junus MB, et al. The American College of Rheumatology 1990 criteria for th classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72 (Pubitemid 20098653)
2. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010;62(5):600-10
3. Kohnen R, Farber L, Spath M. The assessment of vegetative and functional symptoms in fibromyalgia patients: the tropisetron experience. Scand J Rheumatol 2004;33(Suppl 119):67-71 (Pubitemid 39180193)
4. Koeppe C, Schneider C, Thieme K, et al. The influence of 5HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol 2004;33(Suppl 119):24-7 (Pubitemid 39180182)
5. Ray SR, Brouillard D, Simpson CS, et al. Dysautonomia among patients with fibromyalgia: a non-invasive assessment. J Rheumatol 2000;27:2660-5
6. Lapossy E, Gasser P, Hrycaj P, et al. Cold induced vasospasm in patients with fibromyalgia and chronic low back pain in comparison to healthy subjects. Clin Rheumatol 1994;13:442-5 (Pubitemid 24287990)
7. Seidel M, Weinreich GF, Stratz T, Muller W. 5HT3 receptor antagonists regulate autonomic cardial dysfunction in primary fibromyalgia syndrome. Rheumatol Int 2007;27:1025-30 (Pubitemid 47246595)
8. Gracely RH, Petzke F, Wolf JM, Crauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-43 (Pubitemid 34525843)
9. Stratz T, Schochat T, Farber L, et al. Are there subgroups in fibromyalgia? J Musculoskelet Pain 1995;3(Suppl 1):15
10. Endresen GKM. Fibromyalgia: a rheumatological diagnosis. Rheumatol Int 2007;27(11):999-1004
11. Kelemen J, Stratz T, Muller W. Secondary fibromyalgia. Fortsch Med 1998;116:31-6
12. Muller W, Schneider EM, Stratz T. The classification of fibromyalgia syndrome. Rheumatol Int 2007;27:1005-10 (Pubitemid 47246592)
13. de Souza JB, Goffaux P, Julien N, et al. Fibromyalgia subgroups: profiling distinct subgroups using the Fibromyalgia Impact Questionnaire. A preliminary study. Rheumatol Int 2009;29(5):509-15
14. Calandre EP, Garcia-Carrillo J, Garcia-Leiva JM, et al.. Subgrouping patients with fibromyalgia according to the results of the fibromyalgia impact questionnaire: a replication study. Rheumatol Int 2010. [Epub ahead of print]
15. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain threshold and psychological factors. Arthritis Rheum 2004;50:2716-17
16. Thieme K, Turk DC, Flor H. Comorbid depression and anxiety in fibromyalgia syndrome: relationship to somatic and psychosocial variables. Psychosom Med 2004;66:837-44 (Pubitemid 39552866)
17. Hauser W, Bernardy K, Arnold B. Fibromyalgia - a somatoform (pain) disorder? Schmerz 2006;20:128-39
18. Oppenheim RW. Cell death during development of the nervous system. Ann Rev Neurosci 1991;14:453-501
19. Seidel MF, Herguijuela M, Forkert R, Otten U. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2010;40(2):109-26
20. Seidel M, Tsalik J, Vetter H, Muller W. Substance P in rheumatic diseases. Curr Rheum Rev 2007;3:17-30 (Pubitemid 46603431)
21. Lembeck F, Hozer P. Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979;310:175-83 (Pubitemid 10179568)
22. Roberts MH. Pharmacology of putative neurotransmitters and receptors: 5-hydroxytryptamine. Prog Brain Res 1988;77:329-38
23. Seidel MF, Fiebich BL, Ulrich-Merzenich G, et al. Serotonin mediates PGE(2) overexpression through 5-HT(2A) and 5-HT(3) receptor subtypes in serum-free tissue culture of macrophage-like synovial cells. Rheumatol Int 2008;28(10):1017-22
24. Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, et al. The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. Int Immunopharmacol 2010;10(9):1010-16
25. Berberich F, Hoheisel U, Mense S, Scheppar P. Fine muscle afferent fibers and inflammation: changes in discharge behaviour and influence on gamma motoneurones. In: Schmidt RF, Schaible H-G, Vahle-Hinz C, editors, Fine afferent nerve fibers in pain. VCH-Verlag, Weinheim; 1987. p. 165-75
26. Diehl H, Hoheisel U, Mense S. Histological and neurophysiological changes induced by carrageenan in skeletal muscle of cat and rat. Agents Actions 1988;25:210-13 (Pubitemid 19007241)
27. Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005;114:295-302 (Pubitemid 40279112)
28. Mense S. Neurobiological concepts of fibromyalgia - the possible role of descending spinal tracts. Scand J Rheumatol 2000;29(Suppl 113):24-9 (Pubitemid 32016432)
29. Riering K, Rewerts C, Zieglgansberger W. Analgetic effects of 5HT3 receptor antagonists. Scand J Rheumatol 2004;33(Suppl 119):19-23 (Pubitemid 39180181)
30. Fiebich BL, Akundi RS, Lieb K, et al. Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol 2004;33(Suppl 119):28-32 (Pubitemid 39180183)
31. Giordano J, Daleo C, Sacks SM. Topical ondansetron attenuates nociceptive and antiinflammatory effects of intradermal capsaicin in humans. Eur J Pharmacol 1998;354:R13-14 (Pubitemid 28410243)
32. Kukushkin ML, Igonkina SI. Role of 5HT3 receptors in the mechanism of central pain syndrome. Bull Exp Biol Med 2003;135:552-5 (Pubitemid 37368981)
33. Zeitz KP, Guy N, Malberg AB, et al. The 5HT3 subtype of serotonin receptorcontributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 2002;22:1010-19 (Pubitemid 34141780)
34. Mense S, Simons DG, Russel JJ. Muscle pain understanding its nature, diagnosis and treatment. Lippincott, Williams and Williams, Philadelphia; 2001
35. Papadopoulos IA, Glorgiou PE, Katsimtri PP, Drossos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 receptor antagonist: a pilot study. Clin Rheumatol 2000;19:6-8 (Pubitemid 30123233)
36. Muller W, Stratz T, Schochat T, Mennet P. The therapy of fibromyalgia with 5HT3 receptor antagonists. Z Rheumatol 1994;53(Suppl 1):24
37. Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5HT3 receptor antagonist. Scand J Rheumatol 2000;29(Suppl 113):49-54
38. Oliver B, Van Wijngaarden I, Soudij W. 5HT(3) receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol 2000;10:77-95 (Pubitemid 30120037)
39. Varga B, Farber L, Kohnen R, et al. Four week therapy with the 5HT3 receptor antagonist tropisetron in fibromyalgia. Akt Rheumatol 2000;25:43-50 (Pubitemid 30316628)
40. Haus U, Varga B, Stratz T, et al. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000;29(Suppl 113):55-8 (Pubitemid 32016438)
41. Stratz T, Varga B, Muller W. The influence of depression on the therapy of fibromyalgia. Z Rheumatol 2003;62:42-5
42. Stratz T, Kees F, Muller W. Do cytochrome enzymes influence the therapeutic effect of fibromyalgia? Drugs Exp Clin Res 2003;29:91-4 (Pubitemid 36975515)
43. Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000;29(Suppl 113):59-62 (Pubitemid 32016439)
44. Spath M, Stratz T, Neeck G, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004;33:267-70 (Pubitemid 39180172)
45. Tolk J, Kohnen R, Muller W. Intravenous treatment of fibromyalgia with 5HT3 receptor antagonist tropisetron in a rheumatological practice. Scand J Rheumatol 2004;33(Suppl 119):72-5 (Pubitemid 39180194)
46. Wolf H. Preclinical and clinical pharmacology of 5HT3 receptor antagonists. J Scand Rheumatol 2000;29(Suppl 113):37-45 (Pubitemid 32016435)
47. Haus U, Spath M, Farber L. Spectrum of use and tolerability of 5HT3 receptor antagonists. Scand J Rheumatol 2004;333(Suppl 119):12-18 (Pubitemid 39180180)
48. Stratz T, Muller W. The effect of the 5HT3 receptor antagonist tropisetron on pain caused by secondary fibromyalgia. Fortschr Med 2002;120:17-20 (Pubitemid 34456870)
49. Stratz T, Muller W. Treatment of systemic sclerosis with the 5HT3 receptor antagonist tropisetron. Scand J Rheumatol 2004;33(Suppl 119):59-62 (Pubitemid 39180191)
50. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1-beta, interleukin 6 and tumor necrosis factor alpha in skin of patients with fibromyalgia. J Rheumatol 2003;30:148-50
51. Mulington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann NY Acad Sci 2001;933:201
52. Gur A, Karakoc M, Erdogan S, et al.Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002;20:753-60 (Pubitemid 35446964)
53. Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines play an aetiopathogenetic role in fibromyalgia. A hypothesis and pilot study. Rheumatology 2001;40:743-9
54. Muller W, Schneider M, Joos T, et al. A model for subgrouping fibromyalgia syndrome. Schmerz 2007;21(5):424-9
55. Oen K, Robinson DR, Nickerson P, et al. Familial seropositive rheumatoid arthritis in north American native families: effects of shared epitope and cytokine genotypes. J Rheumatol 2005;32:983-91 (Pubitemid 40828067)
56. Burckhardt CS, O'Reilly CA, Wiens NA, et al. Assessing depression in fibromyalgia patients. Arthritis Care Res 1994;7:35-9 (Pubitemid 24082118)
57. Fassbender K, Samborski W, Kellner M, et al. Tender points, depressive and functional symptoms. Comparison between fibromyalgia and major depression. Clin Rheumatol 1997;16:76-9 (Pubitemid 27101296)
58. Hudson JL, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Dis Clin North Am 1996;22:285-303 (Pubitemid 26149680)
59. Anderberg UM, Martendottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35 (Pubitemid 30230793)
60. Arnold LM, Rosen A, Pritchett YL, et al. A randomized double-blind placebocontrolled trial of duloxetine in the treatment of women with fibromyalgia with and without major depression. Pain 2005;119:5-15 (Pubitemid 41752960)
61. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of minacipram in patients with fibromyalgia. J Rheumatol 2005;32:1975-85
62. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a metaanalysis. J Gen Intern Med 2000;15:659-66
63. Thomas E, Blotmann F. Are antidepressants effective in fibromyalgia? Joint Bone Spine 2001;69:531-3
64. Uceyler N, Hauser W, Sommer C. A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. Arthritis Rheum 2008;59(9):1279-98
65. Hauser W, Bernardy K, Uceyler N, et al. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009;301(2):198-209
66. Hauser W, Eich W, Herrmann M, et al. Fibromyalgia syndrome - Classification, diagnosis and treatment. Dtsch Aerztebl Int 2009;106:383-92
67. Goldenberg DL. Update on the treatment of fibromyalgia. Bull Rheum Dis 2004;53:1-7
68. Ginsberg F, Mancaux A, Joos E, et al. A randomized placebo-controlled trial of substained-release amitriptylin in primary fibromyalgia. J Musculoskelet Pain 1996;4:37-47
69. Lucchelli A, Santagostino-Barbone MG, Candura SM, Tonini M. The interaction of antidepressant drugs with central and peripheral (enteric) 5HT3 and 5HT4 receptors. Br J Pharmacol 1995;114:1017-25
70. Wolfe F, Cathey MA, Hawley DJ. A double blind placebo-controlled trial of fluoxetin in fibromyalgia. Scand J Rheumatol 1994;23:255-9
71. Arnold LM, Hess EA, Hudson JI, et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetin in treatment of women with fibromyalgia. Am J Med 2002;112:191-7
72. Patkar AA, Masand PS, Krulewicz S, et al. randomized, controlled, trial of release paroxetin in fibromyalgia. Am J Med 2007;120:448-54 (Pubitemid 46656247)
73. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9 (Pubitemid 26378576)
74. Uceyler N, Offenbacher M, Petzke F, et al. New treatment options for fibromyalgia: critical appraisal of duloxetine. Neuro Psychiatr Dis Treat 2008;4:525-9 (Pubitemid 352037831)
75. Scholz BA, Hammonds CL, Boomeshine CS. Duloxetine for the management of fibromyalgia syndrome. J Pain Res 2009;2:99-108
76. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004
77. Nagaoka S, Ohno M, Sekiguchi A. An open-label clinical trial of milacipran in fibromyalgia syndrome with comorbid depressive symptoms. Int J Psychiatr Clin Pract 2004;8:7-51
78. Lyseng-Williamson KKA, Siddiqui M, Asif A. Pregabalin: a review of its use in fibromyalgia. Drugs 2008;68:2205-23
79. Arnold LM, Russel RW, Florian H, et al. Pregabalin monotherapy for relief of symptoms of fibromyalgia syndrome: analysis of two double-blind, randomized, placebo-controlled trials. Ann Rheum Dis 2007;66(Suppl II):62
80. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin 1008-105 study group. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo controlled trial. Arthritis Rheum 2005;52:1264-73
81. Crofford LJ, Simpson SI, Young JP, et al. The fibromyalgia relapse evaluation and efficacy for durability of meaningful relief trial, a 6-month, double blind, placebo-controlled trial of pregabalin as treatment of fibromyalgia syndrome. Ann Rheum Dis 2007;66(Suppl II):61
82. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprin. A meta-analysis. Arthritis Rheum 2004;51:9-13
83. Childers MK, Borenstein D, Brown RL, et al. Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: a randomized trial. Curr Med Res Opin 2005;21:1485-93 (Pubitemid 41368582)
84. Vaeroy H, Abrahamsen A, Forre O, et al. Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clin Rheumatol 1989;8:245-50 (Pubitemid 20122951)
85. Bennet RM, Schein J, Kosinski MR, et al. Impact of fibromyalgia pain on health-relatet quality of life before and after treatment with tramadol/ acetaminophen. Arthritis Rheum 2005;53:519-25
86. Muller W, Stratz T. Using 5HT3 receptor antagonists in fibromyalgia patients treated with morphine. Akt Rheumatol 2003;28:266-8 (Pubitemid 37413265)
87. Bennet RM, Clark SC, Walczyk J. A randomized double-blind, placebo controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31 (Pubitemid 28163166)
88. Sorensen J, Bengtsson A, Backman E, et al. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocain and ketamine. Scand J Rheumatol 1995;24:360-5 (Pubitemid 26041936)
89. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist in patients with fibromyalgia receiving concomitant medication. Arthritis Rheum 2005;52:2495-505 (Pubitemid 41117437)
90. Raphael JH, Southall JL, Treharne GJ, Kitas GD. Efficacy and adverse effects of intravenous lidocain therapy. BMC Musculoskelet Disord 2002;3:1-8 (Pubitemid 38994405)
91. Hannonen P, Malminiemi K, Yli-Kerttula U, et al. A randomized, double-blind, placebo-controlled study of moclobenide and amitriptyline in the treatment of fibromyalgia in female without psychiatric disorder. Br J Rheumatol 1998;37:1279-86
92. Scharf MB, Baumann M, Berkowitz DV. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010;37(10):2156-66
93. Staud R. Pharmacological treatment of fibromyalgia syndrome: new developments. Drugs 2010;70:1-14
94. Egle UT. Somatoform disorders - an update. MMW Fortschr Med 2005;147:6-14
95. Thieme K, Cromnica-Ihle E, Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. Arthritis Rheum 2003;49:314-20 (Pubitemid 36682397)
96. Montoya R, Sitges C, Carda-Herrera M, et al. Abnormal affective modulation of somatosensory brain processing among patients with fibromyalgia. Psychosom Med 2005;57:957-63 (Pubitemid 43740110)
97. May A. Review: chronic pain may change the structure of the brain. Pain 2008;137:7-15
98. Simons DG, Travell J. Myofascial pain dysfunction. The trigger point manual. 2nd edition. Williams and Williams, Baltimore; 1999
99. O2 measurement in taut back musculature (M. erector spinae). Z Rheumatol 1999;49:208-16
100. Shah JP, Phillips T, Danoff JV, Gerber L. A novel microanalytical technique for assaying soft tissue demonstrates significant quantitative biochemical differences in 3 clinically distinct groups: normal, latent and active. Arch Phys Med Rehabil 2003;84:abstract 17
101. Hong CZ, Hsuch TC. Difference in pain relief after trigger point injection in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil 1996;77:1161-6
102. Muller W, Stratz T. Local treatment of tendinopathies and myofascial painsyndrome with the 5HT3 receptor antagonist tropisetron. Scand J Rheumatol 2004;33(Suppl 119):44-8 (Pubitemid 39180187)
103. Muller W, Kelemen J, Stratz T. Spinal factors in the generation of fibromyalgia. Rheumatol 1998;57(Suppl 2):36-42
104. Lapossy E, Maleitzke R, Hrycaj P, et al. The frequency of transition of chronic low back pain to fibromyalgia. Scand J Rheumatol 1995;24:29-33
105. Samborski W, Stratz T, Kretzmann WM, et al. Analysis on occurrence of vegetative and functional complains in low back pain in comparison with fibromyalgia. Z Rheumatol 1991;50:21-2